Such a deal would not be the last. Settlements show no sign of abating, for two main reasons.First, whatever the merits of the case against J J, it is not clear that companies arechanging their ways. The benefits of aggressive marketing often outweigh the cost ofsettlements. Aaron Kesselheim of Harvard University tracked sales of Neurontin, a drugapproved for epilepsy but prescribed for much more. By 2004, when Pfizer paid $430m inpenalties, annual sales had reached $2.7 billion.
这样的交易不会是最后一笔,问题的解决并不表明这种情况有所减少,这有两个主要原因,第一,不管这起针对强生的案件价值几何,我们都弄不清楚这些公司是否已改邪归正。积极的营销带来的利益常常超过解决争端的成本,哈佛大学的阿伦?凯泽尔海姆对批准为治疗癫痫、实际上用途更广的处方药镇顽癫进行了跟踪后发现,到2004年,辉瑞支付的罚款为4.3亿美元,而这种药每年销售已达27亿美元。
Second, there is ample appetite to sue. Barack Obama s health-care law included newmeasures to fight fraud. For every $1 spent in such cases, the Justice Department boasts itgets $7 in return. Whistleblowers keep coming forward: last year they tooted in recordnumbers. And states are getting fiercer: a judge in Arkansas recently ordered J J to pay$1.1 billion for violating the state s version of the False Claims Act.
【2015考研英语阅读强生公司走出困境】相关文章:
最新
2016-10-18
2016-10-11
2016-10-11
2016-10-08
2016-09-30
2016-09-30